AIMS To determine the benefits and toxicity of different corticosteroid regimes in preventing relapse in steroid responsive nephrotic syndrome.
DESIGN Meta-analysis of randomised controlled trials.
SUBJECTS Twelve trials involving 868 children aged 3 months to 18 years.
MAIN OUTCOME MEASURE Frequency of relapse.
RESULTS A meta-analysis of five trials, which compared two months of prednisone with three months or more in the first episode, showed that the longer duration significantly reduced the risk of relapse at 12–24 months (relative risk 0.73; 95% confidence interval 0.60 to 0.89) without an increase in adverse events. There was an inverse linear relation (relative risk 1.382 (SE 0.215) − 0.133 (SE 0.048) duration;r 2 = 0.66; p = 0.05) between the duration of treatment and risk of relapse.
CONCLUSIONS Children in their first episode of steroid responsive nephrotic syndrome should be treated with prednisone for at least three months, with an increase in benefit being shown for up to seven months of treatment.
- nephrotic syndrome
- corticosteroid therapy
- systematic review
Statistics from Altmetric.com
Corticosteroid therapy has been used in childhood nephrotic syndrome since the 1950s. Of children who present with their first episode, the majority of children have minimal change disease and 90–95% will respond to steroid therapy.1 2 With steroid therapy, mortality has fallen from 35%3 to 3%4 because of a reduction in serious infections. Because of this dramatic before–after evidence that corticosteroids improve the outcome of nephrotic syndrome, oral corticosteroids are the first line treatment of a child presenting with idiopathic nephrotic syndrome. No properly controlled prospective trials of corticosteroids compared to placebo were carried out.
Nephrotic syndrome is a potentially chronic disease with about 70% of patients suffering a relapsing course and being at risk of the adverse effects of steroid treatment. A standard prednisone regimen developed by the International Study of Kidney Disease in Children (ISKDC)5 and the Arbeitsgemeinschaft für Pädiatrische Nephrologie (APN)6 for the initial attack is widely used. This consists of daily prednisone for four weeks followed by intermittent prednisone5 (three consecutive days out of seven) or alternate day prednisone6 for four weeks.
Using data from several multicentre studies, it has been recommended7 8 that the dose and duration of corticosteroid therapy should exceed that used in the standard regime. However, the optimal dose and duration of prednisone or other steroid agent that is most beneficial in maintaining remission and associated with least toxicity is not clear. The aim of this study is to assess the benefits and harms of corticosteroid therapy in the management of childhood nephrotic syndrome by conducting a systematic review and meta-analysis of randomised controlled trials. The information will assist clinicians in their decision making and identify to researchers questions that remain to be answered.
Randomised and quasi-randomised trials of corticosteroid agents in steroid responsive nephrotic syndrome (SRNS) were identified from Medline (1966 to July 1998), Embase (1988 to July 1998), and the Cochrane Controlled Trials Register (Cochrane Library Issue 2, 1998). The databases were searched using optimally sensitive strategies for the identification of randomised controlled trials developed for the Cochrane Collaboration,9 10 combined with text words and subject headings for nephrotic syndrome, lipoid nephrosis, child, and steroid. Reference lists of review articles, relevant trials, nephrology textbooks, and proceedings of scientific meetings were also searched. Investigators known to be active in the field were also contacted to seek information about any unpublished trials.
Titles were screened by one reviewer (EH), who retained articles in which children with SRNS were treated with corticosteroid agents only. Abstracts were reviewed independently for study eligibility by two reviewers (EH, JK). Studies were selected if they were randomised or quasi-randomised trials, if they involved children aged 3 months to 18 years in their initial or subsequent episode of SRNS,11if they compared different durations, total doses, or other dose strategies of prednisone or other corticosteroid agent, and if follow up data for six months or more were available. Studies involving children with steroid resistant nephrotic syndrome, congenital nephrotic syndrome, or nephrotic syndrome associated with other glomerulonephritides were excluded. Studies reported in non-English language journals were translated before assessment. Where more than one publication of one trial existed, only the publication with the most complete data was included.
The quality of studies was assessed by two reviewers (EH, JK) without blinding to authorship using the method of Crowther and Henderson-Smart.12 Discrepancies were resolved in discussion with a third reviewer (JC). The quality items assessed were allocation concealment, intention to treat analysis, completeness of follow up, and blinding of outcome assessment because these are known to influence the true treatment effect.13
Data extraction was carried out independently by two reviewers (EH, JK). Disagreements were resolved in consultation with a third reviewer (JC). The standard steroid regime advocated by ISKDC5 and APN6 was compared with other regimes where possible. The primary outcome measure was the prevention of relapse as measured by the number of children with and without relapse at six months or more of the study. Secondary outcome measures sought were the number who developed frequently relapsing nephrotic syndrome,5 mean relapse rate per patient, mean length of time to next relapse, cumulative corticosteroid dosage, and adverse events (reduced growth rate, hypertension, cataracts, glaucoma, psychological disorders, infections, thromboses, osteoporosis).
For dichotomous outcomes the relative risks (RR), risk differences (RD), and number needed to treat (NNT) for individual studies were calculated and summary effect measures calculated in RevMan14 using the random effects model. The random effects model takes into account the between study variability as well as the within study variability. A fixed effects model was also used to test for the robustness of the analysis and outliers. Heterogeneity was analysed using the χ2 test with an α of 0.1 used for statistical significance. Weighted mean differences (WMD) were calculated from pooled data for continuous scales of measurement. To ensure independence in trials with two or more experimental arms, only one experimental arm could be included in the analyses. As we wished to examine a wide range of doses and durations of therapy, we chose to include the experimental group with the longest duration of treatment when trials had more than one experimental arm. Examination of the effects of study quality, patient type (initial episode, relapsing), and different interventions was attempted by subgroup analysis. To determine whether RR was constant across studies or whether it varied depending on plausible effect modifiers such as dose and duration of treatment and the risk of relapse in the control group (control event rate), meta-regression was performed.15 For the analyses, the total dose of prednisone administered for induction of the first remission was calculated from the treatment protocol described.
Of the 491 studies identified, 14 were identified by full text review to be randomised controlled trials. Two articles6 16 were duplicate publications, so the article containing the most information16 was included. One trial17 in abstract form only was excluded as follow up data were only available to three months. One study18 was available in abstract form only. Additional information on the results was not available from the investigators. Thus 12 trials involving 868 children were evaluated. Table 1 shows the characteristics of the seven trials18-24 in children in their initial episode of SRNS. Five trials20-24 compared standard therapy (60 mg/m2/day prednisone for four weeks followed by 40 mg/m2 on alternate days or on three consecutive days out of seven for two months), with regimes of at least three months of therapy comprising 1–2 months of daily and 1.5–6 months of alternate day therapy. In one of these trials22 standard therapy was compared with two experimental regimes. The outcomes from the experimental group treated for six months were included in the analyses. One of these trials22 excluded those children who became steroid dependent. One trial19 compared standard therapy with a shorter duration of treatment and one trial18 compared five months with one year of therapy. Table 2 shows the aims and characteristics of five trials16 25-28 in children with relapsing SRNS. Each study explored different treatment regimes aimed at inducing and/or maintaining remission.
Table 3 shows the assessment of study quality. Randomisation was adequately concealed in five studies. In two studies20 22the numbers of children in the treatment and control groups differed considerably, and in the Polish study22 it was stated that the parents could influence which treatment group their child was assigned to. In the Japanese study20 the calculated total protocol dose (4620 mg/m2) exceeded the dose administered (3132 (SD 417) mg/m2) suggesting that the protocol was not adhered to in all patients. Only three studies were analysed on an intention to treat basis.22 26 28 Fewer than 10% of participants were excluded in seven studies.19-24 26Only one study28 reported that outcome assessment was blinded. However, most studies reported the primary outcome measure using the ISKDC's definition of relapse.5
OUTCOME OF CHILDREN IN THEIR FIRST EPISODE OF SRNS
Meta-analysis of the five studies20-24 involving 334 children, in which the experimental groups received a total calculated induction dose of prednisone of between 2922 and 4620 mg/m2administered over three to seven months, showed that the longer durations and higher doses resulted in significant reductions in relapse rate, the number of relapses per patient per year, and the number of children who relapsed frequently (table 4, fig 1). There was no increase in serious adverse events, infections, or cumulative steroid dose reported. No significant heterogeneity was shown (fig 1). Only one21 of the five studies showed adequate allocation concealment, so subgroup analysis based on study quality was not possible. A single study20 showed that a total dose and duration less than the standard regime resulted in a significantly higher relapse rate at 12 months (RR 1.46; 95% confidence interval (CI) 1.01 to 2.12) and a shorter time to first relapse (WMD −3.00; 95% CI −4.94 to −1.06). A further single trial18showed no evidence that the relapse rate was significantly reduced by giving prednisone for one year compared with five months (RR 0.76; 95% CI 0.51 to 1.13).
In the six studies19-24 comparing standard therapy with other doses and durations of therapy, there was no significant association between the rate of relapse in the control groups treated for only two months (control event rate) and the relative risk for relapse at 12–24 months (r 2 = 0.18, p = 0.4). Combining these six studies (fig 2) showed that the risk of relapse was significantly reduced with increased duration (RR = 1.382 (SE 0.215) − 0.133 duration (SE 0.048);r 2 = 0.66; p = 0.05) and dose (RR 1.701 (SE 0.292) − 0.000264 dose (SE 8.630E-05);r 2 = 0.70; p = 0.04) of prednisone. To explore whether duration or dose of prednisone determined the treatment response, we plotted the ratio of total dose to duration against relative risk (RR) to determine the average monthly dose (fig 3). This suggested that a reduction in risk of relapse was primarily associated with an increase in duration not dose, as an increase in dose per month appeared to be associated with increased rather than decreased relative risk for relapse.
CHILDREN WITH RELAPSING SRNS
Tables 2 and 5 show the characteristics and results of the studies16 25-28 in children with relapsing SRNS. Alternate day therapy16 was significantly more effective than intermittent therapy in maintaining remission in frequently relapsing children during six months of therapy but there was no difference by 12 months. Single daily dosing27 was as effective as multiple daily dosing in achieving and maintaining remission in children who relapsed frequently. Deflazacort28 significantly reduced the number of children who relapsed during therapy and reduced the relapse rate among those who relapsed without significant differences in side effects. Comparison of therapeutic interventions used in children with their first episode of nephrotic syndrome with those used in children with relapsing nephrotic syndrome was not possible as no studies compared the same interventions in these different patient groups.
Treatment of children in their first episode of SRNS with prednisone for between three and seven months compared with two months results in fewer children experiencing relapses within 12–24 months without a notable increase in adverse effects. In addition there is a linear dose–response relation between the risk of relapse and the duration and total induction dose of prednisone.
Examination of the relation between the risk for relapse and the ratio of dose to duration suggests that longer duration of treatment is more important than total dose in reducing the risk. The relative risk of relapse at 12–24 months falls by 0.133 (13%) for every month increase in therapy to seven months (fig 2). Table 6 illustrates the relation between the duration of prednisone therapy and the relapse rate when treated for two months. The higher the relapse rate with two months of therapy (control event rate), the greater the magnitude of the treatment effect expected with increased durations of prednisone therapy. The control event rate in six studies ranged from 48% to 91% with a mean of 66%. With relapse rate of 66% in children treated for two months, the event rate would fall by 9% for every increase by one month in the duration of therapy so that treatment for six months would reduce the risk of relapse by 36% (4 × 9%) to 30% compared with two months. Ideally clinicians should know the control event rate in their local population so that they can determine how much increasing the duration of therapy will improve the outcome among their patients.
The treatment regime for the initial episode of SRNS was originally determined by the ISKDC.5 Subsequently the APN showed that alternate day therapy6 was more effective that intermittent administration in maintaining remission and that three months of therapy was more effective than two in preventing relapse.21 These data led to the recommendation that children should receive six weeks of daily prednisone followed by six weeks of alternate day prednisone.7 Recently published recommendations8 for initial treatment of nephrotic syndrome in children state that daily prednisone should be used for four to six weeks, followed by alternate day therapy for four to six weeks. However, neither of the authors based their conclusions on a systematic review and meta-analysis of the randomised trials included here.
In children with relapsing SRNS a single small study showed that the synthetic heterocyclic oxazoline glucocorticoid deflazacort28 maintained 66% more children with steroid dependent SRNS in remission during treatment in comparison with prednisone given in an equivalent dose. No significant increase in adverse events was shown but the study was underpowered to detect adverse events. Deflazacort may offer an alternative to prednisone for maintaining remission in children with steroid dependent SRNS. Further randomised controlled trials of deflazacort are required to confirm its efficacy. If deflazacort is confirmed to be more effective than prednisone, the benefits and toxicity of this medication in comparison with non-corticosteroid agents should be examined.
Study quality was generally poor with only five studies18 19 21 26 28 showing adequate allocation concealment. In only one21 of the five studies included in the meta-analysis was allocation concealment considered adequate. Trials with inadequate allocation concealment can exaggerate the efficacy of the experimental treatment by 30–40%13 and meta-analyses of low quality trials may overestimate the benefit of therapy.29 Despite these quality issues, no significant heterogeneity was shown and there was a consistent reduction in the number of children experiencing relapse with the longer duration of treatment.
Publication bias resulting from the exclusion of some unpublished trials cannot be totally excluded. Publication bias30 may result in an overestimate of treatment efficacy if the unpublished trials show no treatment effect. Formal testing using funnel plots or regression analysis was not possible because of the small number of studies. Responses from four senior investigators active in the field did not reveal any unpublished studies.
From the data, it was not possible to determine whether durations of treatment exceeding seven months would result in further reductions in the risk for relapse. No evidence of benefit through prolonging treatment to 12 months was shown in one study.18 Similarly the efficacy of total induction doses outside the range of doses used in the trials cannot be determined. No increase in toxicity was shown in the trials. However, individual trials were not designed specifically to study toxicity and so were underpowered for the detection of side effects of corticosteroids. Thus the low reported incidence of side effects with prolonged duration of corticosteroids could be explained by a type 2 statistical error and may not be generalisable to larger groups of children.
From this meta-analysis of randomised controlled trials it can be concluded that children in their first episode of nephrotic syndrome should be treated for at least three months, with an increase in benefit being shown for up to seven months of treatment. In a population with a baseline risk for relapse of 60% with two months of prednisone, daily prednisone for four weeks followed by alternate day therapy for six months would be expected to reduce the number of children experiencing a relapse by about 40%.
This work was supported by the Australian Kidney Foundation. The authors wish to thank Professors Barratt, Brodehl, Broyer, and Ponticelli for responding to our requests for information about unpublished trials. This work has been presented in part at the 35th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology (Brisbane, 1999), the Annual Scientific Meeting of the Royal Australasian College of Physicians (Melbourne, 1999), and the 33rd Annual Meeting of the European Society for Paediatric Nephrology (Prague, 1999).